CN Patent

CN101784270A — 包含吡喃葡萄糖基-取代的苯衍生物的药物组合物

Assigned to Boehringer Ingelheim International GmbH · Expires 2010-07-21 · 16y expired

What this patent protects

本发明涉及权利要求1的药物组合物，其包含吡喃葡萄糖基取代的苯衍生物与DPP IV抑制剂，其适于治疗或预防一或多种选自I型糖尿病、II型糖尿病、葡萄糖耐量降低及高血糖的病症。另外，本发明涉及预防或治疗代谢病症及相关病症的方法。

USPTO Abstract

本发明涉及权利要求1的药物组合物，其包含吡喃葡萄糖基取代的苯衍生物与DPP IV抑制剂，其适于治疗或预防一或多种选自I型糖尿病、II型糖尿病、葡萄糖耐量降低及高血糖的病症。另外，本发明涉及预防或治疗代谢病症及相关病症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN101784270A
Jurisdiction
CN
Classification
—
Expires
2010-07-21
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.